N-glycosylated antibody

1. A monoclonal antibody or fragment thereof that recognizes the Lewis Y antigen and is derived from a parental monoclonal antibody that recognizes the Lewis Y antigen, characterized in that the Fc region of said antibody or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity as compared to the ADCC and CDC activity of said parental monoclonal antibody, wherein said antibody does not contain a core fucosylation.

2. The antibody according to claim 1 , characterized in that the ADCC activity is increased at least 20 fold.

3. The antibody according to claim 1 , characterized in that the ADCC activity is increased at least 25 fold.

4. The antibody according to claim 1 , characterized in that the ADCC activity is increased at least 40 fold.

5. The antibody according to claim 1 , characterized in that the ADCC activity is increased at least 60 fold.

6. The antibody according to claim 1 , characterized in that the CDC activity is at least 20% decreased.

7. The antibody according to claim 1 , characterized in that the CDC activity is at least 40% decreased.

8. The antibody according to claim 1 , characterized in that it carries a bi-secting N-acetylglucosamine group.

9. The antibody according to claim 1 , characterized in that it is a humanized antibody.

10. The antibody according to claim 1 which is IgG or a fragment thereof.

11. The antibody according to claim 10 which is IgG1 or a fragment thereof.

12. A pharmaceutical preparation containing an antibody according to any one of claims 1 to 11 in a pharmaceutically acceptable carrier or diluent.